ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 1, 2010, Pages 35-46

  Shen, Jianfeng ^a,b,c   Wu, Yalan ^a   Xu, Jing Ying ^a,b   Zhang, Jingfa ^a,b   Sinclair, Stephen H ^d   Yanoff, Myron ^d   Xu, Guoxu ^e   Li, Weiye ^a,b,d,f   Xu, Guo Tong ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^f PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE ORANGE; ADVANCED GLYCATION END PRODUCT; BROXURIDINE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; ETHIDIUM BROMIDE; GLYOXAL; MITOGEN ACTIVATED PROTEIN KINASE; PROPIDIUM IODIDE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B; APOPTOSIS REGULATORY PROTEIN; BAD PROTEIN, RAT; BAX PROTEIN, RAT; BCL2L1 PROTEIN, RAT; MESSENGER RNA; NEUROPROTECTIVE AGENT; PROTEIN BCL X;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRESS; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; IN VITRO STUDY; MALE; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROPROTECTION; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGAN CULTURE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RAT; RETINA NERVE CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; METABOLISM; ORGAN CULTURE TECHNIQUE; OXIDATIVE STRESS; PHOSPHORYLATION; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; GLYCOSYLATION END PRODUCTS, ADVANCED; GLYOXAL; IN SITU NICK-END LABELING; MALE; NEUROPROTECTIVE AGENTS; ORGAN CULTURE TECHNIQUES; OXIDATIVE STRESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RETINAL NEURONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; UP-REGULATION;

EID: 75749093639     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3544     Document Type: Article

References (60)

1. Yamagishi S, Nakamura K, Matsui T. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Curr Drug Discov Technol. 2006;3:83-88.
2. Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des. 2008;14:962-968.
3. Munch G, Schinzel R, Loske C, et al. Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation end products. J Neural Transm. 1998;105:439-461.
4. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med. 1997;23:134-147.
5. Reber F, Geffarth R, Kasper M, et al. Graded sensitiveness of the various retinal neuron populations on the glyoxal-mediated formation of advanced glycation end products and ways of protection. Graefes Arch Clin Exp Ophthalmol. 2003;241:213-225.
6. Cherian L, Goodman JC, Robertson C. Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J Pharmacol Exp Ther. 2007;322:789-794.
7. King CE, Rodger J, Bartlett C, Esmaili T, Dunlop SA, Beazley LD. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol. 2007;205:48-55.
8. Liu R, Suzuki A, Guo Z, Mizuno Y, Urabe T. Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro. J Neurochem. 2006;96:1101-1110.
9. Stitt AW. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol. 2001;85: 746-753.
10. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab. 2001;27: 535-542.
11. Antonsson B, Martinou JC. The Bcl-2 protein family. Exp Cell Res. 2000;256:50-57.
12. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol. 2003;39:615-647.
13. Tan Y, Demeter MR, Ruan H, Comb MJ. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem. 2000;275:25865-25869.
14. Srinivasan A, Li F, Wong A, et al. Bcl-xL functions downstream of caspase-8 to inhibit Fas-and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells. J Biol Chem. 1998;273:4523-4529.
15. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG, Green DR. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem. 1999;274:2225-2233.
16. Silva M, Benito A, Sanz C, et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem. 1999;274:22165-22169.
17. Kretz A, Happold CJ, Marticke JK, Isenmann S. Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation. Mol Cell Neurosci. 2005;29:569-579.
18. Kilic U, Kilic E, Soliz J, Bassetti CI, Gassmann M, Hermann DM. Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. FASEB J. 2005;19: 249-251.
19. Kashii S, Mandai M, Kikuchi M, et al. Dual actions of nitric oxide in N-methyl-D-aspartate receptor-mediated neurotoxicity in cultured retinal neurons. Brain Res. 1996;711:93-101.
20. Seigel GM, Sun W, Wang J, Hershberger DH, Campbell LM, Salvi RJ. Neuronal gene expression and function in the growth-stimulated R28 retinal precursor cell line. Curr Eye Res. 2004;28:257-269.
21. Cury-Boaventura MF, Pompeia C, Curi R. Comparative toxicity of oleic acid and linoleic acid on Jurkat cells. Clin Nutr. 2004;23: 721-732.
22. Costa PM, Ferreira PM, Bolzani Vida S, et al. Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol In Vitro. 2008;22:854-863.
23. Sunstrom NA, Gay RD, Wong DC, Kitchen NA, DeBoer L, Gray PP. Insulin-like growth factor-I and transferrin mediate growth and survival of Chinese hamster ovary cells. Biotechnol Prog. 2000;16: 698-702.
24. Zhang J, Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci. 2008;49:732-742.
25. Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RH. Retinal pathology in Alzheimer's disease, II: regional neuron loss and glial changes in GCL. Neurobiol Aging. 1996;17:385-395.
26. Buckingham BP, Inman DM, Lambert W, et al. Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J Neurosci. 2008;28:2735-2744.
27. Yatsiv I, Grigoriadis N, Simeonidou C, et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J. 2005;19:1701-1703.
28. Chong ZZ, Li F, Maiese K. Erythropoietin requires NF-κB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res. 2005;2: 387-399.
29. Brettschneider J, Widl K, Schattauer D, Ludolph AC, Tumani H. Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis. Neurosci Lett. 2007;416:257-260.
30. Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A. 1994;91:7742-7746.
31. Vairano M, Dello Russo C, Pozzoli G, et al. Erythropoietin exerts antiapoptotic effects on rat microglial cells in vitro. Eur J Neurosci. 2002;16:584-592.
32. Chang YK, Choi DE, Na KR, et al. Erythropoietin attenuates renal injury in an experimental model of rat unilateral ureteral obstruction via anti-inflammatory and antiapoptotic effects. J Urol. 2009; 181:1434-1443.
33. White L, Fisher JW, George WJ. Role of erythropoietin and cyclic nucleotides in erythroid cell proliferation in fetal liver. Exp Hematol. 1980;8(suppl 8):168-181.
34. Chen ZY, Asavaritikrai P, Prchal JT, Noguchi CT. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J Biol Chem. 2007;282:25875-25883.
35. Shangari N, O'Brien PJ. The cytotoxic mechanism of glyoxal involves oxidative stress. Biochem Pharmacol. 2004;68:1433-1442.
36. Reber F, Kasper M, Siegner A, Kniep E, Seigel G, Funk RH. Alteration of the intracellular pH and apoptosis induction in a retinal cell line by the AGE-inducing agent glyoxal. Graefes Arch Clin Exp Ophthalmol. 2002;240:1022-1032.
37. Reed JC, Jurgensmeier JM, Matsuyama S. Bcl-2 family proteins and mitochondria. Biochim Biophys Acta. 1998;1366:127-137.
38. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899-1911.
39. Tsujimoto Y. Bcl-2 family of proteins: life-or-death switch in mitochondria. Biosci Rep. 2002;22:47-58.
40. van Delft MF, Huang DC. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res. 2006;16:203-213.
41. Pregi N, Vittori D, Perez G, Leiros CP, Nesse A. Effect of erythropoietin on staurosporine-induced apoptosis and differentiation of SH-SY5Y neuroblastoma cells. Biochim Biophys Acta. 2006;1763: 238-246.
42. Zhande R, Karsan A. Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-κB-independent upregulation of Bcl-xL. Am J Physiol Heart Circ Physiol. 2007;292:H2467-H2474.
43. Datta SR, Ranger AM, Lin MZ, et al. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell. 2002;3:631-643.
44. Tao W, Kurschner C, Morgan JI. Bcl-xS and Bad potentiate the death suppressing activities of Bcl-xL, Bcl-2, and A1 in yeast. J Biol Chem. 1998;273:23704-23708.
45. Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol. 2006;18:132-138.
46. Zhang F, Wang S, Cao G, Gao Y, Chen J. Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia. Neurobiol Dis. 2007;25:45-53.
47. Byts N, Samoylenko A, Fasshauer T, et al. Essential role for Stat5 in the neurotrophic but not in the neuroprotective effect of erythropoietin. Cell Death Differ. 2008;15:783-792.
48. Zhang F, Signore AP, Zhou Z, Wang S, Cao G, Chen J. Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms. J Neurosci Res. 2006;83:1241-1251.
49. Um M, Lodish HF. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. J Biol Chem. 2006;281: 5648-5656.
50. Seigel GM, Mutchler AL, Imperato EL. Expression of glial markers in a retinal precursor cell line. Mol Vis. 1996;2:2.
51. Xue L, Murray JH, Tolkovsky AM. The Ras/phosphatidylinositol 3-kinase and Ras/ERK pathways function as independent survival modules each of which inhibits a distinct apoptotic signaling pathway in sympathetic neurons. J Biol Chem. 2000;275:8817-8824.
52. Sun P, Watanabe H, Takano K, Yokoyama T, Fujisawa J, Endo T. Sustained activation of M-Ras induced by nerve growth factor is essential for neuronal differentiation of PC12 cells. Genes Cells. 2006;11:1097-1113.
53. Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol. 2003;138:1107-1118.
54. Liu FT, Goff LK, Hao JH, Newland AC, Jia L. Increase in the ratio of mitochondrial Bax/Bcl-XL induces Bax activation in human leukemic K562 cell line. Apoptosis. 2004;9:377-384.
55. Sinha-Datta U, Taylor JM, Brown M, Nicot C. Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt. Apoptosis. 2008;13:33-40.
56. Han Z, Hong L, Han Y, et al. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res. 2007;26:261-268.
57. Fu QL, Wu W, Wang H, Li X, Lee VW, So KF. Upregulated endogenous erythropoietin/erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension. Cell Mol Neurobiol. 2008;28:317-329.
58. Zhong YS, Liu XH, Cheng Y, Min YJ. Erythropoietin with retrobulbar administration protects retinal ganglion cells from acute elevated intraocular pressure in rats. J Ocul Pharmacol Ther. 2008;24:453-459.
59. Weishaupt JH, Rohde G, Polking E, Siren AL, Ehrenreich H, Bahr M. Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 2004;45:1514-1522.
60. Yamasaki M, Mishima HK, Yamashita H, et al. Neuroprotective effects of erythropoietin on glutamate and nitric oxide toxicity in primary cultured retinal ganglion cells. Brain Res. 2005;1050:15-26.